There are currently 240 clinical trials in Hartford, Connecticut looking for participants to engage in research studies. Trials are conducted at various facilities, including Hartford Hospital, Connecticut Children's Medical Center, Smilow Cancer Hospital Care Center at Saint Francis and Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
NCT04844606
Recruiting
The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD). The study will last about 172 weeks and may include up to 44 visits. Additional treatment may be available to participants via a Continued Access Period.
Gender:
ALL
Ages:
Between 2 years and 19 years
Trial Updated:
07/22/2025
Locations: Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
Register for Updates
A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of Schizophrenia
NCT06791122
Recruiting
This study is open to people aged 18 years or older with schizophrenia. People can join the study if they are willing to use a smartphone app called CT-155. This app is being developed to help people with schizophrenia manage their negative symptoms. The purpose of this study is to gather new information on CT-155. Researchers want to see how well it works, how well participants use the study app, and how it affects the use of health care services. Participants use the app for 16 weeks. They m... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Institute of Living, Hartford, Connecticut
Conditions: Schizophrenia
Register for Updates
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
NCT00736749
Recruiting
This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated in Children's Oncology Group studies may allow doctors learn more about the long-term effects of cancer treatment and help them reduce problems related to treatment and improve patient quality of life.
Gender:
ALL
Ages:
All
Trial Updated:
07/22/2025
Locations: Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Hematopoietic Cell Transplantation Recipient, Leukemia, Solid Tumor
Register for Updates
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
NCT05076175
Recruiting
The purpose of this study is to evaluate the effectiveness and safety of ozanimod (RPC1063) in achieving and maintaining clinical remission. Ozanimod will be administered orally to pediatric participants with moderate to severe active ulcerative colitis (UC) who have had an inadequate response to conventional therapy.
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
07/22/2025
Locations: Local Institution - 0007, Hartford, Connecticut
Conditions: Colitis, Ulcerative
Register for Updates
A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC)
NCT05429320
Recruiting
The purpose of this study is to see whether receiving local ablative therapy (LAT) when minimal residual disease/MRD levels are rising can reduce MRD levels and control metastatic non-small cell lung cancer/NSCLC longer compared to systemic therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Hartford Healthcare ALLIANCE (Data collection only), Hartford, Connecticut
Conditions: Non-small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Nsclc, NSCLC Stage IV, Minimal Residual Disease, Non Small Cell Lung Cancer Metastatic
Register for Updates
Prophylactic Reinforcement of Ventral Abdominal Incisions Trial
NCT03911700
Recruiting
This trial is being conducted to evaluate the efficacy of Phasix™ Mesh implantation at the time of midline fascial closure compared to primary suture closure in preventing a subsequent incisional hernia in subjects at risk for incisional hernia after open midline laparotomy surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Hartford Hospital, Hartford, Connecticut +1 locations
Conditions: Open Midline Laparotomy
Register for Updates
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598
Recruiting
The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective than the durvalumab and placebo combination in part B in participants with unresectable KRAS G12C-mutant non-small cell lung cancer. The study may last up to 3 years for each participant.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Hartford Hospital (HH), Hartford, Connecticut
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)
NCT02815891
Recruiting
TARGET-NASH is a longitudinal observational cohort study of patients being managed for NASH and related conditions across the entire spectrum NAFLD in usual clinical practice. TARGET-NASH is a research registry of patients with NAFL or NASH within academic and community real-world practices maintained in order to assess the safety and effectiveness of current and future therapies.
Gender:
ALL
Ages:
2 years and above
Trial Updated:
07/22/2025
Locations: Connecticut Gastroenterology, Hartford, Connecticut +1 locations
Conditions: Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Register for Updates
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
NCT04301843
Recruiting
Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study in combination with etoposide for subjects with relapsed/refractory neuroblastoma.
Gender:
ALL
Ages:
31 years and below
Trial Updated:
07/21/2025
Locations: Connecticut Children's Hospital, Hartford, Connecticut
Conditions: Neuroblastoma
Register for Updates
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
NCT05489887
Recruiting
This is a prospective, multicenter clinical trial in subjects with newly diagnosed high-risk neuroblastoma to evaluate the efficacy and safety of administering naxitamab with standard induction therapy. The initial chemotherapy will include 5 cycles of multi-agent chemotherapy. Naxitamab will be added to all 5 Induction cycles. We hypothesize that the addition of anti-GD2 therapy to induction chemotherapy will result in improved end of induction responses and improved survival.
Gender:
ALL
Ages:
Between 12 months and 21 years
Trial Updated:
07/21/2025
Locations: Connecticut Children's Hospital, Hartford, Connecticut
Conditions: High-risk Neuroblastoma
Register for Updates
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
NCT05968326
Recruiting
The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in participants with resected pancreatic ductal adenocarcinoma (PDAC) who have not received prior systemic anti-cancer treatment for PDAC and have no evidence of disease after surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: St. Francis Hospital and Medical Center, Hartford, Connecticut
Conditions: Adenocarcinoma, Pancreatic Ductal
Register for Updates
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT05923073
Recruiting
The purpose of this study is to evaluate the clinical and endoscopic efficacy of guselkumab in pediatric participants with Crohn's Disease (CD) at the end of maintenance therapy (Week 52) among participants who were in clinical response to guselkumab at Week 12.
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
07/18/2025
Locations: Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Crohn's Disease
Register for Updates